مصطلحات الفهرس: meta analysis, multiple myeloma/dt [Drug Therapy], observational study, oncology, ovary cancer/dt [Drug Therapy], peer review, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, prostate cancer/dt [Drug Therapy], QT prolongation/si [Side Effect], randomized controlled trial (topic), review, systematic review, venous thromboembolism/si [Side Effect], abiraterone/ae [Adverse Drug Reaction], abiraterone/ct [Clinical Trial], abiraterone/dt [Drug Therapy], aflibercept/ae [Adverse Drug Reaction], aflibercept/ct [Clinical Trial], androgen receptor/ec [Endogenous Compound], axitinib/ae [Adverse Drug Reaction], axitinib/ct [Clinical Trial], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], cediranib/ae [Adverse Drug Reaction], cediranib/ct [Clinical Trial], cetuximab/ae [Adverse Drug Reaction], cetuximab/ct [Clinical Trial], cytochrome P450 family 17/ec [Endogenous Compound], enzalutamide/ae [Adverse Drug Reaction], enzalutamide/ct [Clinical Trial], enzalutamide/dt [Drug Therapy], epidermal growth factor receptor 2/ec [Endogenous Compound], estrogen receptor alpha/ec [Endogenous Compound], estrogen receptor beta/ec [Endogenous Compound], Flt3 ligand/ec [Endogenous Compound], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/dt [Drug Therapy], nintedanib/ae [Adverse Drug Reaction], nintedanib/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], panitumumab/ct [Clinical Trial], pazopanib/ae [Adverse Drug Reaction], pazopanib/ct [Clinical Trial], platelet derived growth factor alpha receptor/ec [Endogenous Compound], platelet derived growth factor beta receptor/ec [Endogenous Compound], protein Ret/ec [Endogenous Compound], Raf protein/ec [Endogenous Compound], ramucirumab/ae [Adverse Drug Reaction], ramucirumab/ct [Clinical Trial], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], sunitinib/ae [Adverse Drug Reaction], sunitinib/ct [Clinical Trial], tamoxifen/ae [Adverse Drug Reaction], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/ct [Clinical Trial], thalidomide/dt [Drug Therapy], transcription factor/ec [Endogenous Compound], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], unclassified drug, vandetanib/ae [Adverse Drug Reaction], vandetanib/ct [Clinical Trial], vandetanib/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], vasculotropin receptor 1/ec [Endogenous Compound], vasculotropin receptor 3/ec [Endogenous Compound], cytochrome P450 family 17a1/ec [Endogenous Compound], lymphoid transcription factor ikzf1/ec [Endogenous Compound], lymphoid transcription factor ikzf3/ec [Endogenous Compound], molecularly targeted therapy, arterial thromboembolism/si [Side Effect], breast cancer/dt [Drug Therapy], cardiology, cardiotoxicity/si [Side Effect], castration resistant prostate cancer/dt [Drug Therapy], clinician, Cochrane Library, cohort analysis, congestive heart failure/si [Side Effect], controlled study, drug megadose, Embase, female, general practice, heart left ventricle ejection fraction, human, hypertension/si [Side Effect], low drug dose, lung cancer/dt [Drug Therapy], male, Medline, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27204Test
JNCI Cancer Spectrum
LibKey Link

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: Click here for full text options
LibKey Link

مصطلحات الفهرس: neutropenia/si [Side Effect], priority journal, retrospective study, sepsis/si [Side Effect], thrombocytopenia/si [Side Effect], thrombosis/si [Side Effect], treatment response, unspecified side effect/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cisplatin/iv [Intravenous Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], etoposide/iv [Intravenous Drug Administration], granulocyte colony stimulating factor/dt [Drug Therapy], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], tumor lysis syndrome/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], advanced cancer/th [Therapy], aged, anemia/si [Side Effect], article, autologous stem cell transplantation, cancer combination chemotherapy, febrile neutropenia/dt [Drug Therapy], febrile neutropenia/pc [Prevention], febrile neutropenia/si [Side Effect], female, heart disease/si [Side Effect], herpes zoster/si [Side Effect], human, major clinical study, male, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], multiple myeloma/th [Therapy], mycosis/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37228Test
Leukemia and Lymphoma
Click here for full text options
LibKey Link

مصطلحات الفهرس: cancer survival, clinical outcome, comorbidity, drug efficacy, drug tolerability, follicular lymphoma/di [Diagnosis], follicular lymphoma/dt [Drug Therapy], human, immunoregulation, infection/si [Side Effect], maintenance therapy, medical decision making, nonhodgkin lymphoma/di [Diagnosis], nonhodgkin lymphoma/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], patient monitoring, patient preference, priority journal, progression free survival, review, second cancer/si [Side Effect], survival time, symptom, T cell depletion, treatment duration, treatment response, tumor volume, bendamustine/ae [Adverse Drug Reaction], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], CD20 antibody/cb [Drug Combination], CD20 antibody/dt [Drug Therapy], obinutuzumab/dt [Drug Therapy], prednisolone/ae [Adverse Drug Reaction], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], overall survival, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], lenalidomide/dt [Drug Therapy], advanced cancer/di [Diagnosis], age, asymptomatic disease/di [Diagnosis], Australia, cancer combination chemotherapy, cancer diagnosis, cancer immunotherapy, cancer recurrence, cancer staging, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35707Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: neutropenia/si [Side Effect], priority journal, retrospective study, sepsis/si [Side Effect], thrombocytopenia/si [Side Effect], thrombosis/si [Side Effect], treatment response, unspecified side effect/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cisplatin/iv [Intravenous Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], etoposide/iv [Intravenous Drug Administration], granulocyte colony stimulating factor/dt [Drug Therapy], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], tumor lysis syndrome/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], advanced cancer/th [Therapy], aged, anemia/si [Side Effect], article, autologous stem cell transplantation, cancer combination chemotherapy, febrile neutropenia/dt [Drug Therapy], febrile neutropenia/pc [Prevention], febrile neutropenia/si [Side Effect], female, heart disease/si [Side Effect], herpes zoster/si [Side Effect], human, major clinical study, male, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], multiple myeloma/th [Therapy], mycosis/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37228Test
Leukemia and Lymphoma
LibKey Link

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35895Test
LibKey Link

مصطلحات الفهرس: dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], melphalan/po [Oral Drug Administration], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], thalidomide/po [Oral Drug Administration], maintenance therapy, aged, cancer combination chemotherapy, cancer survival, elderly care, human, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], priority journal, review, salvage therapy, bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], bortezomib/iv [Intravenous Drug Administration], dexamethasone/cb [Drug Combination], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30418Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: stroma cell, autologous stem cell transplantation, cancer recurrence, cell cycle arrest, cytogenetics, drug efficacy, drug megadose, drug potentiation, drug safety, human, immunity, immunomodulation, infection/si [Side Effect], multiple myeloma/dt [Drug Therapy], multiple myeloma/di [Diagnosis], multiple myeloma/th [Therapy], neutropenia/si [Side Effect], phase 3 clinical trial (topic), priority journal, randomized controlled trial (topic), review, apoptosis, thrombocytopenia/si [Side Effect], treatment duration, treatment response, venous thromboembolism/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/it [Drug Interaction], dexamethasone/dt [Drug Therapy], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/it [Drug Interaction], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pd [Pharmacology], melphalan/ct [Clinical Trial], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pomalidomide/dt [Drug Therapy], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], thalidomide/dt [Drug Therapy], antineoplastic activity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28291Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, multiple myeloma/dt [Drug Therapy], somnolence/si [Side Effect], treatment response, Bence Jones protein/ec [Endogenous Compound], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], clodronic acid/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], idarubicin/cb [Drug Combination], idarubicin/dt [Drug Therapy], immunoglobulin heavy chain/ec [Endogenous Compound], immunoglobulin light chain/ec [Endogenous Compound], lenalidomide/dt [Drug Therapy], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pamidronic acid/dt [Drug Therapy], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/dt [Drug Therapy], vincristine/cb [Drug Combination], zoledronic acid/dt [Drug Therapy], vincristine/dt [Drug Therapy], adult, aged, article, biological therapy, cancer chemotherapy, cancer relapse, case report, clinical feature, constipation/si [Side Effect], disease activity, disease course, drug megadose, female, human, low drug dose, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31818Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: stroma cell, autologous stem cell transplantation, cancer recurrence, cell cycle arrest, cytogenetics, drug efficacy, drug megadose, drug potentiation, drug safety, human, immunity, immunomodulation, infection/si [Side Effect], multiple myeloma/dt [Drug Therapy], multiple myeloma/di [Diagnosis], multiple myeloma/th [Therapy], neutropenia/si [Side Effect], phase 3 clinical trial (topic), priority journal, randomized controlled trial (topic), review, apoptosis, thrombocytopenia/si [Side Effect], treatment duration, treatment response, venous thromboembolism/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/it [Drug Interaction], dexamethasone/dt [Drug Therapy], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/it [Drug Interaction], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pd [Pharmacology], melphalan/ct [Clinical Trial], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pomalidomide/dt [Drug Therapy], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], thalidomide/dt [Drug Therapy], antineoplastic activity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28291Test
LibKey Link